Navigation Links
TRiUS Data Suggests That Testim® Significantly Improved Sexual Function in Hypogonadal Men
Date:11/3/2011

MALVERN, Pa., Nov. 3, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced the release of clinical practice data from the Testim Registry in the United States (TRiUS). This study showed that daily administration of Testim® 1% (testosterone gel) resulted in significantly improved sexual function and increased total testosterone levels in men with hypogonadism, often referred to as low testosterone. Sexual function assessments from TRiUS, which followed patients in clinical practice for a 12-month period, were published in the November issue of the Journal of Sexual Medicine.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

"These data are an important look at testosterone replacement therapy's (TRT) impact on sexual function in hypogonadal men," said Mohit Khera, M.D., Director of the Laboratory for Andrology Research at Baylor College of Medicine and lead study investigator.  "The improved level of sexual function seen in the study participants suggests that the increases of total testosterone achieved with TRT may correlate with the improvement in their self-reported sexual function."

Investigators assessed data from 271 TRiUS patients and evaluated the correlation between changes in the patients' Brief Male Sexual Function Inventory (BMSFI) scores and their mean total testosterone levels after 12 months of Testim therapy. The BMSFI assessed patients' self-reported sexual drive/libido, erectile function, ejaculatory function, and level of bother/sexual problems. After 12 months of TRT, mean total BMSFI scores significantly increased from baseline from 27.4 +/- 10.3 to 33.8 +/- 9.8 (P < 0.001) and mean total testosterone concentrations increased from 9.28 +/- 4.84 to 17.37 +/- 8.61 nmol/L (p<0.001). Regression analysis indicated that the increased total BMSFI score was significantly associated wi
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate
2. Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA
3. Trius to Present at the Stifel Nicolaus Healthcare Conference
4. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
5. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
7. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
8. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
9. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
10. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
11. Trius Doses First Patient in Antibacterial Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... May 23, 2012 Medical Tactile, Inc. (MTI), ... Incorporated, today announced that they have developed a pre-commercial ... sensor technology for breast cancer screening.  ... Komen Foundation, 1.6 million women worldwide were diagnosed with ... the disease. Although early detection is the best means ...
(Date:5/23/2012)... Kraton Performance Polymers, Inc. (NYSE: "KRA"), ... or SBCs , and PolyOne Distribution, a ... and solutions, announce the execution of a distribution ... PolyOne product line. "Kraton Polymers ... IR products due to their deep knowledge about ...
(Date:5/23/2012)... 2012  Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... for its U.S. phase 2 clinical trial, T ... G reater E fficacy T rial ... in patients with non-tuberculous mycobacterial (NTM) lung disease. ... to support current NTM treatment recommendations, and no new ...
Breaking Medicine Technology:Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 2Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 3Medical Tactile, Inc. Announces a 3G-Wireless System for Breast Cancer Screening 4Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 2Cariflex™ Polyisoprene Products by Kraton Performance Polymers Added to PolyOne Distribution Product Line 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 2Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 3Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 4Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease 5Resource savvy communities generate healthy sustainable changes 15181 1Resource savvy communities generate healthy sustainable changes 15181 2Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 1Radiation Oncology Services of America Inc to Work With Washington University on Quality Assurance Initiative 10552 2U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 1U S Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014 10547 2
... Type 2 Diabetes Using Emisphere,s Eligen(R) ... ... Emisphere,Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a ... study used a delivery-agent-based approach using Emisphere,s Eligen(R),technology, and was conducted ...
... meets primary endpoints in ENGAGE Trial, KENILWORTH, ... ) announced today that corifollitropin alfa, its,experimental, sustained ... Phase III ENGAGE trial, according to data presented ... of the,European Society of Human Reproduction and Embryology ...
Other Medicine Technology:Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 2Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 3Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 2Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant 3
(Date:5/23/2012)... Reporter , , TUESDAY, May 22 (HealthDay News) -- ... procedure, which involves threading a camera through the ... But a new study has found that patients ... less time-consuming CT-based colon scan. Colonoscopy ... colon cancer screening. Computed tomography (CT) colonography -- ...
(Date:5/23/2012)... The number of viral infections during infancy is not ... new study from researchers in the Netherlands. While viral ... childhood, this association was due in part to decreased ... particularly rhinovirus, are thought to be a risk factor ... this association is due to the viruses themselves or ...
(Date:5/23/2012)... A tiny, resilient metal wire designed to gather ... patients with severe heterogeneous emphysema, a subtype of the ... lungs, according to the results of a multicenter international ... wire, called a lung volume reduction coil (LVRC), can ... place of more invasive procedures used to improve the ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... OR Bend Research Inc., a leading ... the expansion of its existing hot-melt extrusion ... 18mm Leistritz twin-screw mixer/extruder. , The ... existing 27mm Leistritz and 19mm Baker Perkins ... continuous high-shear wet-granulation capabilities. Many projects have ...
Breaking Medicine News(10 mins):Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 2Health News:Tiny implanted coil improves lung function in patients with severe emphysema 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4
... 18 Women,s, health and,environmental groups today called on ... wake of product tests released last week by the,Campaign ... an,independent lab, 61 percent (20 samples) contained detectable levels ... lipsticks with the highest lead,content were made by L,Oreal ...
... Decisions Network,(MDN) announces Food and Drug Administration 510(k) ... The MDN-CGS software is used,by hospital nurses to ... administered to patients with elevated levels of blood,glucose, ... to energy for survival. More and more ...
... to Reduce Number Denied by President, a Few in ... 2,000,children will join the ranks of the uninsured, adding ... public health insurance,according to new data released today by ... new analysis, American Families Face Harsh Reality: 2,000 Children,Join ...
... Mass., Oct. 18 Yankee Candle Company,Inc., the ... home fragrance, is,taking action in the fight against ... Logo: http://www.newscom.com/cgi-bin/prnh/20071018/NYTH093LOGO-b ) Yankee Candle ... breast,cancer awareness and research. The company is donating ...
... returning U.S. veterans , , THURSDAY, Oct. 18 (HealthDay News) ... when deciding how best to treat post-traumatic stress disorder ... of the data concludes. , The Institute of Medicine ... Affairs, which noted that about 12.6 percent of personnel ...
... Haas (NYSE:,ROH) announced today that it has ... used as a bonding alternative for pressure,sensitive ... like,door panels, interior pillars, instrument panels and ... before seen or thought possible,in an aqueous ...
Other Medicine News:Health News:Health Groups Call on Cosmetic Giant L'Oreal to Remove Lead From Lipstick 2Health News:FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software 2Health News:Families Face Harsh Reality: 2,000 Children Join the Uninsured Each Day 2Health News:Yankee Candle Company Sheds Some Light In The Fight Against Breast Cancer 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 2Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 3Health News:Value of Most Post-Traumatic Stress Treatments 'Uncertain' 4Health News:New Water-Based Acrylic Pressure-Sensitive Adhesive Defeats Heat and Humidity Issue 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: